Axinesis
Axinesis develops CE-marked robotic and digital neurorehabilitation devices for upper limb therapy in stroke, cerebral palsy, MS, and Parkinson's patients, selling to European hospitals, rehabilitation centers, and increasingly to home users through tele-rehabilitation platforms.
- Company typePrivate
- Founded2015
- HeadquartersWavre, Belgium
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Axinesis does
Axinesis is a Belgian medical device company founded in 2015 in Wavre that develops CE-marked neurorehabilitation technologies for patients with motor and cognitive disorders, primarily stroke, cerebral palsy, multiple sclerosis, and Parkinson's disease. Its product portfolio spans the full continuum of care: REAplan, an end-effector robot for early intensive auto-adaptive therapy; REAtouch, an interactive 43-inch touch-screen device for uni- and bimanual functional rehabilitation with serious games; REAtouch Lite 2, a portable 32-inch version certified for both clinical and home use; and the REApad and REAtouch Home digital platforms that enable tele-rehabilitation and self-directed home therapy. The core technology combines robotics, therapeutic gamification (over 25 serious games), and REAlab adaptive software that automatically adjusts movement assistance and resistance based on real-time patient performance, with structured kinematic data capture on every movement. The company has produced multiple randomized controlled trials demonstrating non-inferiority or superiority versus conventional therapy and long-lasting effects up to six months post-therapy.
The business model centers on capital equipment sales of CE-marked devices to rehabilitation centers and hospitals through a direct enterprise sales motion with free demonstrations and trials, supplemented by technical support and maintenance services. The portfolio is increasingly complemented by software-driven recurring revenue through REApad and REAtouch Home tele-rehabilitation. Pricing is not publicly disclosed, but the company emphasizes a stated average payback period of two years for buyers. Axinesis sells primarily in Belgium with documented expansion into the Netherlands and maintains a network of academic and clinical partners including UCLouvain, Cliniques universitaires Saint-Luc, CHU Namur, CHU Sainte-Justine, and Polytechnique Montréal, as well as a consortium under BioWin/Walloon Region support developing the FRITE@Home tele-rehabilitation solution.
Axinesis firmographics
Firmographics- Name
- Axinesis
- Legal name
- Axinesis SA
- Website
- https://axinesis.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Axinesis develops CE-marked robotic and digital neurorehabilitation devices for upper limb therapy in stroke, cerebral palsy, MS, and Parkinson's patients, selling to European hospitals, rehabilitation centers, and increasingly to home users through tele-rehabilitation platforms.
- Ownership category
- akta.pro rank
Axinesis industry classification
Industry- Product category
- Neurorehabilitation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Home Health Care Services (62161)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Home Health Care Services (8082)
- akta.pro primary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
- akta.pro secondary industries
- Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics) (HLAHAMAJ), Neurologic Rehabilitation (Stroke, TBI, Parkinson’s, MS) (HSADAIAC), Neurological Rehabilitation Therapy In-Home (e.g., Stroke, Parkinson’s) (HSABADAE), Neurology Telemedicine Platforms (HLALAGAC)
Keywords
Where Axinesis is headquartered
LocationHeadquarters
- HQ city
- Wavre
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
Axinesis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical device hardware sales: Sale of CE-marked neurorehabilitation medical devices including REAplan, REAtouch, and REAtouch Lite. Devices are sold to rehabilitation centers, hospitals, and for home use with pricing based on device configuration.
- Software platform subscriptions: REApad digital neurorehabilitation platform on touchscreen tablet, providing therapeutic exercises and assessment modules for home-based rehabilitation. Platform enables continuity of therapy with personalized programs set up by therapists.
- Technical support and maintenance: Technical support services provided to customers and distributors in Europe, with dedicated support line and remote assistance options.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Devices have proven ROI with average payback time of 2 years |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels8 records
Axinesis product offering
Product offeringCore offering
Axinesis designs, manufactures and sells CE-marked interactive neurorehabilitation devices and digital platforms that combine robotics, therapeutic serious games, and self-adaptive algorithms for upper limb rehabilitation. The portfolio spans the continuum of care from acute hospital rehabilitation (REAplan, REAtouch) to home-based therapy (REAtouch Lite 2, REApad, REAtouch Home), targeting patients with stroke, cerebral palsy, multiple sclerosis, and Parkinson's disease.
Product overview
Axinesis offers a unified portfolio of neurorehabilitation devices and digital platforms for upper limb rehabilitation spanning the complete care continuum. The core product family includes three complementary rehabilitation devices: REAplan® (end-effector robot for intensive auto-adaptive therapy, launched 2017), REAtouch® (interactive device for intensive uni- and bimanual therapy, launched 2020), and REAtouch® Lite 2 (portable version for decentralized and home rehabilitation, launched 2025). Supporting these devices are digital platforms: REApad® (tablet-based neurorehabilitation platform for self-rehabilitation) and REAtouch® Home (tele-rehabilitation software enabling remote therapy adaptation). All products are designed for patients with neurological conditions affecting motor and cognitive function, utilizing therapeutic gamification and self-adaptive algorithms to increase patient motivation and enable intensive functional rehabilitation.
Differentiator
Problem solved
Functional benefit
Products and services
- REAplan® End-effector robot for intensive, auto-adaptive rehabilitation of upper limbs with built-in therapeutic gamification, designed for early rehabilitation in clinical settings.
- REAtouch® Interactive electro-medical device with a 43-inch touch screen for intensive uni- and bimanual therapy using therapeutic serious games, enabling over 1,000 functional movements per session.
- REAtouch® Lite 2 Portable, mobile version of REAtouch® with a 32-inch screen, designed for decentralized upper limb rehabilitation from hospital rooms to home.
- REApad®
Quantifiable outcome
- Significant improvements in gross manual dexterity and upper limb functionality compared to conventional therapy with effects lasting up to 6 months post-therapy
- +3 more outcomes
Companies that use Axinesis
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Axinesis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Axinesis partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and secondary.
- BioWin (Health Cluster of Wallonia)coreHealth cluster supporting the FRITE@Home project which develops tele-rehabilitation solution combining REAtouch Lite and HABIT-ILE method. Project subsidized at €1.8 million by Walloon Region.
- UCLouvain (Université catholique de Louvain)coreAcademic partner in joint consortium with Axinesis, Arsalis, and HELHa developing tele-rehabilitation solution combining REAtouch Lite and HABIT-ILE method. Professor Yannick Bleyenheuft's research team developed the HABIT-ILE method. MSL-IN lab collaborated on REAtouch development and clinical studies.
- HELHa (Haute École Louvain en Hainaut)coreAcademic partner in consortium developing tele-rehabilitation solution combining REAtouch Lite and HABIT-ILE method for home-based rehabilitation.
- ArsaliscoreTechnology partner in consortium developing tele-rehabilitation solution combining REAtouch Lite and HABIT-ILE method.
- Intensive Rehabilitation FoundationcoreDeveloped HABIT-ILE therapy method in collaboration with Axinesis. Collaboration led to development of REAtouch device for applying motor learning principles. Continued partnership for tele-rehabilitation development.
- Cliniques universitaires Saint-LucsecondaryClinical research partner conducting first clinical evaluation of REAtouch Home for stroke patients under Professor Thierry Lejeune's leadership.
- CHU NamursecondaryAcademic hospital partner in neurorehabilitation research and clinical studies.
- CHU Sainte-JustinesecondaryPediatric hospital partner in neurorehabilitation research and clinical studies.
- Polytechnique MontréalsecondaryAcademic partner contributing to robotics and augmented reality research in neurorehabilitation field.
Scale indicators15 records
Recent moves6 records
Expansion highlights6 records
Axinesis competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Axinesis social profiles
Digital presenceAxinesis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Axinesis leadership team
Management profileNumber of profiles
Profiles3 records
Axinesis funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Axinesis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Axinesis
What does Axinesis do?
Axinesis designs, manufactures and sells CE-marked interactive neurorehabilitation devices and digital platforms that combine robotics, therapeutic serious games, and self-adaptive algorithms for upper limb rehabilitation. The portfolio spans the continuum of care from acute hospital rehabilitation (REAplan, REAtouch) to home-based therapy (REAtouch Lite 2, REApad, REAtouch Home), targeting patients with stroke, cerebral palsy, multiple sclerosis, and Parkinson's disease.
Is Axinesis a public or private company?
Axinesis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Axinesis founded?
Axinesis was founded in 2015. It employs 1 to 10 people.
Where is Axinesis based?
Axinesis is headquartered in Wavre, Belgium, in the Europe region.
How does Axinesis make money?
Three revenue lines are on record. Medical device hardware sales are the primary driver. The others are software platform subscriptions and technical support and maintenance.
Does Axinesis have an API?
No public API is recorded for Axinesis.
What industry is Axinesis in?
Axinesis's product category is Neurorehabilitation Medical Devices. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of HLAHAMAJ, Sports & Active Rehabilitation Devices (Adaptive Sports Mobility, Performance Prosthetics). Its NAICS code is 334510 and its SIC code is 3845.